

Poly-Omic Prediction of Complex Traits: OmicKriging

Heather E. Wheeler,¹ Keston Aquino-Michaels,² Eric R. Gamazon,² Vasya Trubetskoy,² M. Eileen Dolan,¹ R. Stephanie Huang,¹ Nancy J. Cox,² Hae Kyung Im^{3*}

1 Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA

2 Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, USA

3 Department of Health Studies, University of Chicago, Chicago, IL, USA

***Correspondence: haky@uchicago.edu**

Abstract

High-confidence prediction of complex traits such as disease risk or drug response is an ultimate goal of personalized medicine. Although genome-wide association studies have discovered thousands of well-replicated polymorphisms associated with a broad spectrum of complex traits, the combined predictive power of these associations for any given trait is generally too low to be of clinical relevance. We propose a novel systems approach to complex trait prediction, which leverages similarity in genetic, transcriptomic or other omics-level data. We translate the omic similarity into phenotypic similarity using a method called Kriging, commonly used in geostatistics and machine learning. Our method called OmicKriging emphasizes the use of a wide variety of systems-level data, such as those increasingly made available by comprehensive surveys of the genome, transcriptome and epigenome, for complex trait prediction. The approach facilitates exploration of the etiology of disease risk or drug response by quantifying specific omic contributions to prediction. Our method is a fast, simple and flexible approach to polygenic, and more generally, poly-omic, prediction. Using seven diseases from the Wellcome Trust Case Control Consortium (WTCCC), we show that our method yields performance similar to more computationally intensive methods when restricted to genotypic data. Using a cellular growth phenotype, we show that integrating mRNA and microRNA data with genotypic data substantially increases performance. We provide guidelines on how to choose the similarity matrices and an R package to implement OmicKriging (<http://www.scandb.org/newinterface/tools/OmicKriging.html>).

Introduction

High-confidence prediction of complex traits is an ultimate goal of personalized medicine. For heritable traits, genotypic similarity contributes to phenotypic similarity. While genome-wide association studies (GWAS) have revealed many statistically significant loci associated with complex traits, the small effect sizes of most loci limit their prediction utility [1]. For most complex traits, an appreciable proportion of phenotypic variance is explained only when polygenic models, rather than single-marker tests, are used [2, 3]. For example, 45% of the variance in human height can be explained using a mixed linear modeling approach (GCTA) that simultaneously considers all 300K common SNPs genotyped [3, 4]. Because this approach does not rely on selection of loci, it is thought to be appropriate for traits with a highly polygenic or infinitesimal genetic architecture [5, 6].

In order to predict phenotypes from genomic data, our approach borrows from the field of geostatistics. Kriging interpolates the value of some geographical measurement such as yearly rainfall at an unobserved location [7–9]. The approach assumes the rainfall measured at nearby locations will be more similar to that at the unmeasured location than rainfall at sites farther away. Kriging uses weights based on the correlation matrix of these locations along with the observed rainfall amounts to predict the rainfall at the unmeasured location. The locations are analogous to individuals and the rainfall amounts are analogous to the phenotype of interest (Figure 1). In our application to complex trait prediction, the notion of distance can be replaced with that of genetic similarity. Close ties between genetic distance and geographic distance have been demonstrated in studies of human population structure. For example, in the analysis of genome-wide genotype data from 3000 Europeans, a geographic map of Europe arose naturally when the first two principal components of the data were plotted [10]. A diagram of the analogy between geostatistical kriging and complex trait prediction is shown in Figure 1. The loose connection between kriging and linear regression is illustrated in Figure 2.

Complex trait prediction using whole-genome data has been previously described [1, 5, 6, 11]. We propose a novel systems approach to predict complex traits, which leverages similarity in genetic, transcriptomic, and/or other omics-level data. Here, we describe our OmicKriging method, apply the method to several human complex traits (cellular growth and seven WTCCC diseases), and provide an R package for implementation.

Results

In implementing OmicKriging, the first step is to construct a similarity matrix or similarity matrices for use in the prediction. Such matrices may include a genetic relationship matrix (GRM) from a set of SNPs, a gene expression correlation matrix (GXM) from gene expression data, or any other correlation matrix derived from omics-level data. Each matrix can be tested individually or in a given weighted combination for phenotype predictive performance. The optimal correlation matrix depends on the genetic architecture of the phenotype. To predict the phenotype of an individual, the weighted average of the remaining individuals' phenotypes is calculated. In the case of SNP data, the weights are comprised of the GRM and pairwise genotype correlations of the unknown individual with the genotypes of those with observed phenotypes. The inclusion of covariates such as principal components from the GRM to correct for population structure or eigengenes calculated from the GXM [12] may also improve the heritability estimate and phenotypic prediction.

In applying OmicKriging, we used a cross-validation approach. We regressed the predicted phenotype on the true phenotype to measure performance. Note that in the OmicKriging method, weights are computed out-of-sample (only an individual's genotype is used to compute pairwise correlations) and should not be compared to reports where the R^2 is computed using parameters estimated from the same data (in-sample). In terms of computational time, the prediction of each test set for a sample size of about 2500 takes less than 30 seconds. When we divided the full sample into 10 test sets, the prediction takes less than five minutes. This first version of the OmicKriging software written in R is not optimized for speed and thus, further optimization is possible.

Cellular phenotype applications

To assess the predictive performance of OmicKriging, we used the intrinsic growth rate (iGrowth) phenotype derived from multiple proliferation measurements in the commonly used HapMap lymphoblastoid cell lines (LCLs) [13]. iGrowth values from 99 LCLs from the HapMap CEU (Northern and Western European ancestry from Utah) and YRI (Yoruba from Ibadan, Nigeria) populations were used in the analysis. The GRM was generated from 2.7 million common SNPs (minor allele frequency > 0.05) from HapMap [14] and the GXM was generated from 13,080 transcript clusters from a previous genome-wide gene expression analysis [15]. The first 10 principal components from the genotype data and the first

10 eigengenes from the expression data were used as covariates in the OmicKriging prediction. We also obtained expression measurements for 201 microRNAs [16] and generated a microRNA expression correlation matrix (MXM). To determine which combination of correlation matrices was best able to predict iGrowth, we weighted the matrices in various combinations and compared the OmicKriging results. Each matrix alone was able to significantly predict iGrowth with the GXM producing the largest correlation ($R^2=0.38$) of the three (Table 1, Figure 3). However, when all three matrices were weighted equally, the prediction improved ($R^2=0.40$). This indicates that combining omics-level data improved the predictive power of OmicKriging over using the GXM alone. When using a larger sample size ($n=159$) for which we had gene expression data, but not microRNA data, we were able to achieve a predictive $R^2=0.51$ based solely on expression data (Table 1).

Clinical phenotype applications

To test the predictive power of OmicKriging using clinical phenotypes, we turned to the seven diseases of the Wellcome Trust Case Control Consortium (WTCCC) [17]. First, for each case/control dataset, all genotyped common SNPs (approximately 400,000) were used to generate a GRM. OmicKriging was run using the correlations from these GRMs and case/control prediction was successful for all seven diseases (Table 2). In an attempt to further improve the prediction, we generated a second GRM for each disease using the SNPs within 100kb of known large effect SNPs (identified outside of WTCCC studies) listed in the The National Human Genome Research Institute GWAS catalog [18] and the Database of Genotypes and Phenotypes (dbGAP) [19]. Equally weighting the first GRM of all SNPs and the second GRM of known loci improved the predictive power of OmicKriging over using just the first GRM alone for Crohn’s disease, rheumatoid arthritis, type 1 diabetes and type 2 diabetes (Table 2, Figure 4). The type 1 diabetes prediction showed the largest improvement when the second GRM was added: the R^2 increased from 0.13 to 0.42 and the area under the ROC curve (AUC) increased from 0.71 to 0.89 (Table 2, Figure 4).

Discussion

We propose a novel systems approach to predict complex traits, which leverages similarity in genetic, transcriptomic and/or other omics-level data. We translate the genomic similarity into phenotypic sim-

ilarity using a method called Kriging, commonly used in geostatistics and machine learning. Here, we construct the genomic similarity using a linear combination of omic correlation matrices but more general similarity matrices can be used. Given the similarity matrix, the prediction is obtained by simply computing a weighted average of the phenotype of individuals in the training set. The weights are provided by the Kriging method, which can be loosely interpreted as a converse of the linear regression method. Our method is a fast, simple and flexible approach to polygenic, and more generally poly-omic, prediction.

The key component of the method is the choice of the similarity matrix. This can be estimated using likelihood-based methods (such as implemented in GCTA [4]) or Bayesian methods (such as BSLMM [11]). We can also take a more pragmatic approach and test multiple weights for each correlation matrix component (large effect GRM, small effect GRM, GXM, etc.) to determine those that maximize prediction performance. When testing the performance of our method, we used our suggested starting values for the weights for the similarity matrix components (Table 3), and no optimization was done. Thus, our reported performance measures are conservative.

Using genotypic, mRNA and microRNA data in HapMap lymphoblastoid cell lines, we predict the cellular intrinsic growth phenotype with a striking out-of-sample R^2 of 40% (51% when $n=159$, for which only genotypic and mRNA expression data were available). We show here that the gene expression correlations are better than the SNP correlations at predicting the growth phenotype and that adding microRNA expression correlations slightly improves the GXM-only prediction (Table 1). Given that 30% of gene expression levels associate with the intrinsic growth phenotype ($FDR < 0.1$) [13], it is perhaps not surprising that gene expression correlations are most useful in predicting this phenotype.

We also successfully predicted seven clinical phenotypes with OmicKriging. We show that our method yields performance similar to other computationally more intensive methods when restricted to genotypic data (Figure 4). For the known autoimmune diseases (Crohn’s disease, rheumatoid arthritis, type 1 diabetes), adding a second GRM of known loci increased the prediction AUC values over a common SNP GRM alone to the AUC values obtained by BSLMM [11] (Figure 4). These autoimmune diseases are known to have multiple associated loci of relatively strong effects, so this prior knowledge was used to improve prediction performance [20]. Unless replicated in an independent study, the results from the WTCCC data were not used to select top SNPs to avoid overfitting the data.

We provide guidelines on how to choose the similarity matrices and an R package to implement the kriging algorithm called OmicKriging (<http://www.scandb.org/newinterface/tools/OmicKriging>).

html).

Methods

Kriging Formula

Within the kriging framework, the predicted phenotype of a test individual is computed as the weighted average of the phenotype of the individuals in the training set.

$$\text{Prediction}(Y_{\text{new}}) = \omega_1 Y_1 + \omega_2 Y_2 + \cdots + \omega_n Y_n \quad (1)$$

where the weights ω_i are a function of all $n(n+1)/2$ pairs of correlations. In the simplest case where no covariates are needed, the weights prescribed by the kriging method are given by

$$\boldsymbol{\omega} = \boldsymbol{\Sigma}^{-1} \boldsymbol{\rho} \quad (2)$$

where $\boldsymbol{\rho}$ is the correlation vector between the test individual and the training individuals and $\boldsymbol{\Sigma}$ is the correlation matrix of the individuals in the training set [7]. Covariates are easily included in the method by using the so called universal kriging approach [7]. Assuming there are p covariates (if only the intercept is considered, $p = 1$), let $\mathbf{z}$ be the p by 1 vector with covariates 1 to p corresponding to the test individual and $\mathbb{Z}$ be the n by p matrix with the p covariates for the n individuals in the training set. The weights become

$$\boldsymbol{\omega} = \boldsymbol{\Sigma}^{-1} (\boldsymbol{\rho} + \mathbb{Z} \mathbf{m}) \quad (3)$$

where $\mathbf{m} = (\mathbb{Z}' \boldsymbol{\Sigma}^{-1} \mathbb{Z})^{-1} (\mathbf{z} - \mathbb{Z}' \boldsymbol{\Sigma}^{-1} \boldsymbol{\rho})$.

Optimal similarity measure

A key component of the success of OmicKriging is understanding which proximity measures translate best into phenotypic similarity. The optimal correlation matrix depends on the underlying genetic and epigenetic architecture of the complex trait.

Under a general additive poly-omic model, the phenotype for individual i can be written as

$$Y_i = a + G_i + T_i + O_i + \cdots + \epsilon_i$$

where

- a is a constant,
- $G_i = \sum_l \beta_l^G X_l^G$ is the additive genetic component and β_l^G is the effect size of the standardized genotype X_l^G ,
- $T_i = \sum_l \beta_l^T X_l^T$ and β_l^T is the effect size of the standardized gene expression X_l^T ,
- $O_i = \sum_l \beta_l^O X_l^O$ is the additive (other) omic component and β_l^O is the effect size of the standardized omic level X_l^O ,
- and ϵ_i is a noise term.

We assume a random effects model for the β 's and the covariances between β 's of different omic origins. For simplicity, we also assume that β 's from the same omic origin are independent.

With these assumptions, the optimal correlation matrix has the form

$$\begin{aligned} \Gamma_{i,j} &= \theta_G \sum_k X_{ik}^G X_{jk}^G + \theta_T \sum_k X_{ik}^T X_{jk}^T + \theta_O \sum_k X_{ik}^O X_{jk}^O + \theta_\epsilon \delta_{ij} \\ &+ \theta_{GT} \left(\sum_{kl} X_{ik}^G X_{jl}^T + \sum_k X_{ik}^T X_{jl}^G \right) \\ &+ \theta_{GO} \left(\sum_{kl} X_{ik}^G X_{jl}^O + \sum_k X_{ik}^O X_{jl}^G \right) \\ &+ \theta_{TO} \left(\sum_{kl} X_{ik}^T X_{jl}^O + \sum_k X_{ik}^O X_{jl}^T \right) \end{aligned}$$

where δ_{ij} is the kronecker delta (1 if $i = j$ and 0 otherwise) and the weights θ_x can be (at least theoretically) estimated using likelihood-based or Bayesian approaches.

In case prior expression quantitative trait loci (eQTL) information is available, it may be possible to restrict the cross-correlation terms to known eQTL pairs (X_k, T_l) . However, care must be taken to preserve positive definiteness of Γ (all eigenvalues must be > 0). In this paper, to keep computations within reach, we ignore the cross-correlation terms.

Genotype-only analysis

LMM model

When only genotypic data are available, the following model is commonly assumed [3]

$$Y = a + \sum_{k=1}^M \beta_k \mathbf{X}_k + \epsilon$$

where the effect sizes β_k 's are assumed to be normally distributed $N(0, \sigma_\beta^2)$, $\mathbf{X}_k$ is the n by 1 vector of standardized genotypic dosage for marker k , and M is the number of genetic markers. In this case, the optimal correlation matrix is given by the genetic relatedness matrix $\mathbb{X}'\mathbb{X}$, where $\mathbb{X}$ is the matrix with genotypic data for all n individuals. Following the Zhou et al. [11] terminology we call this model LMM.

BSLMM model

If the trait has a polygenic background with a handful of known large effect loci, we can leverage that information by using two genetic relatedness matrices and assign comparable weight to each component. This model can be represented as

$$Y = a + \sum_{k=1}^M \beta_k^L \mathbf{X}_k + \sum_{k=1}^M \beta_k \mathbf{X}_k + \epsilon$$

where β_k , $\mathbf{X}$, and M are as defined in the LMM model, β_k^L is zero with probability $1 - \pi$ and normally distributed $N(0, \sigma_\alpha^2)$ with probability π , and $\sigma_\beta^2 < \sigma_\alpha^2$. Again, following the Zhou et al. [11] terminology we call this model BSLMM. In this case, the optimal correlation matrix has the form $\theta_1 \mathbb{X}'\mathbb{X} + \theta_2 \mathbb{X}'_L \mathbb{X}_L$ where $\mathbb{X}$ is the matrix with all genotypic data and $\mathbb{X}_L$ is the matrix of the subset of markers with large effects. We do not attempt to estimate from the data which markers have large effect sizes but use markers published in the NHGRI catalog and the ones within 100kb of them to build a large effect genetic relatedness matrix. When selecting the large effect variants, it is crucial not to use results from the dataset that is being predicted in order to avoid overfitting the data.

Acknowledgments

This work was supported by the Genotype-Tissue Expression project (GTEx) (R01 MH090937), the University of Chicago DRTC (Diabetes Research and Training Center; P60 DK20595), the PAAR NIH/NIGMS grant UO1GM61393, The University of Chicago Cancer Center Support Grant P30 CA014599-36, and the NIH National Research Service Award F32CA165823.

This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113 and 085475.

Author Contributions

H.K.I. conceived the method. H.E.W. and H.K.I. wrote the R package. H.E.W., K.A.-M., E.R.G., V.T. and H.K.I. performed the analyses. M.E.D., R.S.H., and N.J.C. contributed resources and suggestions. H.E.W., E.R.G., and H.K.I. wrote the paper.

References

1. de los Campos G, Gianola D, Allison D (2010) Predicting genetic predisposition in humans: the promise of whole-genome markers. *Nat Rev Genet* 11: 880–886.
2. Purcell S, Wray N, Stone J, Visscher P, O'Donovan M, et al. (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460: 748–752.
3. Yang J, Benyamin B, McEvoy B, Gordon S, Henders A, et al. (2010) Common SNPs explain a large proportion of the heritability for human height. *Nat Genet* 42: 565–569.
4. Yang J, Lee S, Goddard M, Visscher P (2011) GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 88: 76–82.
5. Makowsky R, Pajewski N, Klimentidis Y, Vazquez A, Duarte C, et al. (2011) Beyond missing heritability: prediction of complex traits. *PLoS Genet* 7: e1002051.

6. Ober U, Ayroles J, Stone E, Richards S, Zhu D, et al. (2012) Using whole-genome sequence data to predict quantitative trait phenotypes in *Drosophila melanogaster*. *PLoS Genet* 8: e1002685.
7. Cressie NA (1993) *Statistics for Spatial Data*, revised edition, volume 928. Wiley, New York.
8. Stein ML (1999) *Interpolation of spatial data: some theory for kriging*. Springer Verlag.
9. Im HK, Stein ML, Zhu Z (2007) Semiparametric estimation of spectral density with irregular observations. *J Am Stat Assoc* 102: 726–735.
10. Novembre J, Johnson T, Bryc K, Kutalik Z, Boyko A, et al. (2008) Genes mirror geography within europe. *Nature* 456: 98–101.
11. Zhou X, Carbonetto P, Stephens M (2013) Polygenic modeling with Bayesian sparse linear mixed models. *PLoS Genet* 9: e1003264.
12. Alter O, Brown P, Botstein D (2000) Singular value decomposition for genome-wide expression data processing and modeling. *Proc Natl Acad Sci* 97: 10101–10106.
13. Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, et al. (2012) Mixed effects modeling of proliferation rates in cell-based models: Consequence for pharmacogenomics and cancer. *PLoS Genet* 8: e1002525.
14. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449: 851–861.
15. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, et al. (2008) Evaluation of genetic variation contributing to differences in gene expression between populations. *Am J Hum Genet* 82: 631–640.
16. Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, et al. (2012) Genetic architecture of microRNA expression: Implications for the transcriptome and complex traits. *Am J Hum Genet* 90: 1046–63.
17. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, et al. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447: 661–678.

18. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci* 106: 9362–9367.
19. Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, et al. (2007) The NCBI dbGaP database of genotypes and phenotypes. *Nat Genet* 39: 1181–1186.
20. Visscher PM, Brown MA, McCarthy MI, Yang J (2012) Five years of GWAS discovery. *Am J Hum Genet* 90: 7.

Tables

Table 1. OmicKriging results for iGrowth prediction using various correlation matrices and weights.

GRM weight	GXM weight	MXM weight	Covariates	n	R ²	P-value
1	0	0	PCs,EGs	99	0.31	1.6×10^{-9}
0	1	0	PCs,EGs	99	0.38	1.0×10^{-11}
0	0	1	PCs,EGs	99	0.27	3.0×10^{-8}
0.33	0.33	0.33	PCs,EGs	99	0.40	2.4×10^{-12}
0.5	0.5	NA	PCs,EGs	159	0.33	2.7×10^{-15}
1	0	NA	PCs,EGs	159	0.29	2.5×10^{-13}
0	1	NA	PCs,EGs	159	0.51	4.7×10^{-26}

GRM=genetic relationship matrix, GXM=gene expression matrix, MXM=microRNA expression matrix, PCs=principal components, EGs=eigengenes

Table 2. OmicKriging results for complex disease prediction.

Disease	GRM1 (weight)	GRM2 (weight)	Cases	Controls	R ²	P-value	ROC AUC
Bipolar disorder	all SNPs (1)	NA	2938	1868	0.074	7×10^{-82}	0.657
Bipolar disorder	all SNPs (0.5)	known loci (0.5)	2938	1868	0.049	7×10^{-55}	0.630
Coronary artery disease	all SNPs (1)	NA	2938	1926	0.030	3×10^{-34}	0.598
Coronary artery disease	all SNPs (0.5)	known loci (0.5)	2938	1926	0.034	5×10^{-38}	0.603
Crohn's disease	all SNPs (1)	NA	2938	1748	0.057	5×10^{-62}	0.637
Crohn's disease	all SNPs (0.5)	known loci (0.5)	2938	1748	0.10	3×10^{-114}	0.690
Hypertension	all SNPs (1)	NA	2938	1952	0.036	3×10^{-40}	0.610
Hypertension	all SNPs (0.5)	known loci (0.5)	2938	1952	0.032	1×10^{-36}	0.604
Rheumatoid arthritis	all SNPs (1)	NA	2938	1860	0.070	4×10^{-77}	0.654
Rheumatoid arthritis	all SNPs (0.5)	known loci (0.5)	2938	1860	0.158	5×10^{-181}	0.734
Type 1 diabetes	all SNPs (1)	NA	2938	1963	0.126	4×10^{-145}	0.710
Type 1 diabetes	all SNPs (0.5)	known loci (0.5)	2938	1963	0.416	$< 1 \times 10^{-200}$	0.888
Type 2 diabetes	all SNPs (1)	NA	2938	1924	0.040	1×10^{-44}	0.617
Type 2 diabetes	all SNPs (0.5)	known loci (0.5)	2938	1924	0.055	3×10^{-62}	0.635

GRM=genetic relationship matrix, ROC AUC=receiver operating characteristic area under the curve

Table 3. Suggested initial weights for similarity matrices. These are suggested starting values for the weights of each component similarity matrix. They can be modified in order to maximize out-of-sample prediction. See the Methods section for term definitions.

Model $Y_i = a + \epsilon_i + \dots$	Θ_G	Θ_{GL}	Θ_T	Θ_O	Description
G_i	1	—	—	—	LMM
$G_i^L + G_i$	0.5	0.5	—	—	BSLMM
$G_i + T_i$	0.5	—	0.5	—	LMM+gene expression
$G_i + T_i + O_i$	0.33	—	0.33	0.33	LMM+gene expression+other




Figure 1. Kriging and whole-genome prediction connection. This figure shows the analogous relationships between components of the kriging method used in geostatistics and whole-genome prediction. The prediction at an unobserved location (?) is computed as a weighted average of the variable at observed locations. The weights are functions of the correlation between the rainfall at the new location and the rainfalls at the observed locations. The closer the distance between each observed location and the new location, the higher the weight. In complex trait prediction, locations correspond to individuals, physical proximity corresponds to genetic relatedness. The correlation between two locations or individuals is the key component of this method. In animal breeding approaches, the genetic relatedness matrix or kinship matrix is used. In OmicKriging, a genetic relatedness matrix, a gene expression similarity matrix, or any combination of available high-throughput data similarity measures can be tested for complex trait prediction performance.




Figure 2. Kriging and linear regression connection. In linear regression, we have many observations of Y and predictors and estimate the regression coefficients (weights) as the inverse of the sample covariance matrix of the observed values (covariates) times the sample covariance between the outcome Y and the covariates. In contrast, in kriging, we use weights (estimated from other means) to predict Y . Notice the weights in both cases have the same functional form.




Figure 3. iGrowth prediction using OmicKriging. Predicted versus true iGrowth ($n=99$) using the genetic relationship matrix (GRM) alone, the microRNA expression matrix (MXM) alone, the gene expression matrix (GXM) alone, and all three matrices weighted equally. Among these four weightings, the combination of all three omics matrices predicted iGrowth best, which indicates that the addition of the GRM and MXM improved the prediction over using the GXM alone. The solid black line represents the slope of the regression between the predicted and true values. The red dashed line is the identity line (slope 1, intercept 0).




Figure 4. OmicKriging prediction performs similarly to BSLMM. The area under the ROC curve (AUC) is plotted for three prediction methods for each disease from the WTCCC. The Bayesian Sparse Linear Mixed Model (BSLMM) results are from Zhou et al. [11]. The OmicKriging results use a single common SNP genetic relationship matrix (1GRM) and two equally weighted GRMs of common SNPs and known loci (2GRM) for the predictions. The 1GRM results are similar to BSLMM for BD, CAD, HT, and T2D. The 2GRM results are similar to BSLMM for CD, RA, and T1D, which are known to have multiple associated loci of relatively large effect. The known loci were obtained from studies that did not include the WTCCC data to avoid over-fitting. BD=bipolar disorder, CAD=coronary artery disease, CD=Crohn’s disease, HT=hypertension, RA=rheumatoid arthritis, T1D=type 1 diabetes, T2D=type 2 diabetes.